The chemists and druggists online marketplace will initially serve customers in five metropolitan cities—Bengaluru, Chennai, Hyderabad, Mumbai and Delhi
Phaneesh Murthy-founded PM Health and Life Care (PMHLC) announced the creation of Zigy.com, reportedly India’s first health exchange, integrated with Zigy HealthVault, a patient-controlled electronic health record system. As the first offering, Zigy.com connects chemists and druggists with consumers.
The Zigy.com health exchange uses technology to efficiently connect Indians needing health products and services with doctors, clinics, hospitals, pharmacies, diagnostic labs, and providers of wellness products & services, insurance, home-care services and alternative medicines.
The Zigy HealthVault claims to provide a highly secure and completely confidential way of storing all health-related information for patients and family members. It promises easy retrieval, upon the patient’s authorisation, to enable doctors and other care providers to fully comprehend the case history.
Speaking on the occasion of the launch, Murthy, Co-Founder and Executive Chairman of PMHLC, said, “Zigy is committed to improving the quality of healthcare, affordability and accessibility for a large segment of the Indian population. This is our first step towards realising our dream of a Swastha Bharat.”
The chemists and druggists online marketplace will initially serve customers in five metropolitan cities—Bengaluru, Chennai, Hyderabad, Mumbai and Delhi. The product portfolio on the marketplace will include allopathic, homeopathic, ayurvedic and other wellness products and services. The operations will be extended to 50 cities within 18 months. Over a period of time, Zigy.com will be servicing rural India as well.
According to Hemant Bhardwaj, CEO, MD and Co–Founder, PMHLC, “With our business model which is a win-win for each stakeholder in the ecosystem, we anticipate achieving one million transactions within 12 months of operations.” Zigy is available on both the web and mobile platforms.
Comments are closed.